Regulatory Frameworks for Clinical Trial Data Sharing: Scoping Review
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Background: Although well recognized for its scientific value, data sharing from clinical trials remains limited. Steps toward harmonization and standardization are increasing in various pockets of the global scientific community. This issue has gained salience during the COVID-19 pandemic. Even for agencies willing to share data, data exclusivity practices complicate matters; strict regulations by funders affect this even further. Finally, many low- and middle-income countries (LMICs) have weaker institutional mechanisms. This complex of factors hampers research and rapid response during public health emergencies. This drew our attention to the need for a review of the regulatory landscape governing clinical trial data sharing. Objective: This review seeks to identify regulatory frameworks and policies that govern clinical trial data sharing and explore key elements of data-sharing mechanisms as outlined in existing regulatory documents. Following from, and based on, this empirical analysis of gaps in existing policy frameworks, we aimed to suggest focal areas for policy interventions on a systematic basis to facilitate clinical trial data sharing. Methods: We followed the JBI scoping review approach. Our review covered electronic databases and relevant gray literature through a targeted web search. We included records (all publication types, except for conference abstracts) available in English that describe clinical trial data–sharing policies, guidelines, or standard operating procedures. Data extraction was performed independently by 2 authors, and findings were summarized using a narrative synthesis approach. Results: We identified 4 articles and 13 policy documents; none originated from LMICs. Most (11/17, 65%) of the clinical trial agencies mandated a data-sharing agreement; 47% (8/17) of these policies required informed consent by trial participants; and 71% (12/17) outlined requirements for a data-sharing proposal review committee. Data-sharing policies have, a priori, milestone-based timelines when clinical trial data can be shared. We classify clinical trial agencies as following either controlled- or open-access data-sharing models. Incentives to promote data sharing and distinctions between mandated requirements and supportive requirements for informed consent during the data-sharing process remain gray areas, needing explication. To augment participant privacy and confidentiality, a neutral institutional mechanism to oversee dissemination of information from the appropriate data sets and more policy interventions led by LMICs to facilitate data sharing are strongly recommended. Conclusions: Our review outlines the immediate need for developing a pragmatic data-sharing mechanism that aims to improve research and innovations as well as facilitate cross-border collaborations. Although a one-policy-fits-all approach would not account for regional and subnational legislation, we suggest that a focus on key elements of data-sharing mechanisms can be used to inform the development of flexible yet comprehensive data-sharing policies so that institutional mechanisms rather than disparate efforts guide data generation, which is the foundation of all scientific endeavor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There remains a gap between the recommendations for data sharing and actual practice.95,96”
From Integrity of randomized clinical trials: Performance of integrity tests and checklists requires assessment (2023) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0850 · Cited by 43,565 · cited 1×
“The scoping review is reported according to the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines [37].”
MethodScoping studies: towards a methodological framework
Arksey, H., & O'Malley, L. (2005) · International Journal of Social Research Methodology · doi:10.1080/1364557032000119616 · Cited by 36,742 · cited 2×
“The JBI methodology has outlined six steps for the conduct of a scoping review: (1) identifying the research question; (2) identifying relevant studies; (3) study selection; (4) charting the data, (5) collating, summarizing, and reporting the results; and (6) stakeholder consultations [34-36].”
MethodScoping studies: advancing the methodology
Levac, D., Colquhoun, H., & O'Brien, K. K. (2010) · Implementation Science · doi:10.1186/1748-5908-5-69 · Cited by 15,268 · cited 3×
“The data-coding template was pretested as suggested by Levac et al [36] and Daudt et al [68].”
MethodPage, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262 · cited 1×
“To ensure transparency in the study selection process, the number of records included at each stage was represented in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 chart, along with the reasons for exclusion of studies during the full-text screening [66].”
MethodUpdating guidance for reporting systematic reviews: development of the PRISMA 2020 statement
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., & Moher, D. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.02.003 · Cited by 3,490
Daudt, H. M., van Mossel, C., & Scott, S. J. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-48 · Cited by 1,891 · cited 1×
“The data-coding template was pretested as suggested by Levac et al [36] and Daudt et al [68].”
MethodData Sharing by Scientists: Practices and Perceptions
Tenopir, C., Allard, S., Douglass, K., Aydinoglu, A. U., Wu, L., Read, E., Manoff, M., & Frame, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021101 · Cited by 1,432
Munn, Z., Stern, C., Aromataris, E., Lockwood, C., & Jordan, Z. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0468-4 · Cited by 1,164 · cited 1×
“As we intended to synthesize a fast-growing but fragmented body of literature on regulatory documents for data sharing, we did not follow the typical Population, Intervention, Comparison, and Outcomes or Population, Concept, and Context approach to guide our article selection process because this topic falls beyond th…”
BackgroundBaber, N. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05705.x · Cited by 759
Understanding scoping reviews: Definition, purpose, and process
Peterson, J., Pearce, P. F., Ferguson, L. A., & Langford, C. A. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12380 · Cited by 740
Ethical and Scientific Implications of the Globalization of Clinical Research
Glickman, S. W., McHutchison, J. G., Peterson, E. D., Cairns, C. B., Harrington, R. A., Califf, R. M., & Schulman, K. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsb0803929 · Cited by 710 · cited 2×
“Similar concerns were shared by the public in a high-income setting where widely shared data could be a risk for patient privacy and could give rise to discrimination and exploitation [19].”
BackgroundSharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors
Taichman, D. B., Backus, J., Baethge, C., Bauchner, H., de Leeuw, P. W., Drazen, J. M., Fletcher, J., Frizelle, F. A., Groves, T., Haileamlak, A., et al. (2016) · JAMA · doi:10.1001/jama.2015.18164 · Cited by 254
Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk
Lo, B. (2015) · JAMA · doi:10.1001/jama.2015.292 · Cited by 233
Naudet, F., Sakarovitch, C., Janiaud, P., Cristea, I., Fanelli, D., Moher, D., & Ioannidis, J. P. A. (2018) · BMJ · doi:10.1136/bmj.k400 · Cited by 227
Titles versus titles and abstracts for initial screening of articles for systematic reviews
Mateen, F., Oh, Tergas, Bhayani, & Kamdar (2013) · Clinical Epidemiology · doi:10.2147/clep.s43118 · Cited by 202 · cited 1×
“We used this 2-stage strategy because the evidence suggests that there is no difference between the titles-first and title-abstract–together approaches [65].”
MethodOhmann, C., Banzi, R., Canham, S., Battaglia, S., Matei, M., Ariyo, C., Becnel, L., Bierer, B., Bowers, S., Clivio, L., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018647 · Cited by 194 · cited 1×
“It is one of several cost-effective measures for augmenting a body of evidence in resource-constrained settings and in health emergencies [4].”
BackgroundHow to achieve international action on falsified and substandard medicines
Attaran, A., Barry, D., Basheer, S., Bate, R., Benton, D., Chauvin, J., Garrett, L., Kickbusch, I., Köhler, J. C., Midha, K. K., et al. (2012) · BMJ · doi:10.1136/bmj.e7381 · Cited by 191 · cited 1×
“Concerns over clinical trial data sharing follow IPR-related issues that arise with the sharing of undisclosed trial information—a practice often referred to as “secret trial data” [24,25].”
BackgroundSharing Clinical Trial Data — A Proposal from the International Committee of Medical Journal Editors
Taichman, D. B., Backus, J., Baethge, C., Bauchner, H., de Leeuw, P. W., Drazen, J. M., Fletcher, J., Frizelle, F. A., Groves, T., Haileamlak, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejme1515172 · Cited by 190
What incentives increase data sharing in health and medical research? A systematic review
Rowhani-Farid, A., Allen, M., & Barnett, A. G. (2017) · Research Integrity and Peer Review · doi:10.1186/s41073-017-0028-9 · Cited by 127
Access to Patient-Level Data from GlaxoSmithKline Clinical Trials
Nisen, P., & Rockhold, F. (2013) · New England Journal of Medicine · doi:10.1056/nejmsr1302541 · Cited by 120 · cited 10×
“The trial agencies specified in these documents were a for-profit pharmaceutical firm (GlaxoSmithKline [GSK]-sponsored clinical trials) [72], an academic institution (Yale Open Data Access) [70], a pharmaceutical-academia collaboration (Supporting Open Access for Researchers) [73], and a nonprofit regulatory agency (I…”
BackgroundInfluentialSharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors
Taichman, D. B., Backus, J., Baethge, C., Bauchner, H., de Leeuw, P. W., Drazen, J. M., Fletcher, J., Frizelle, F., Groves, T., Haileamlak, A., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2928 · Cited by 110
Data Sharing For Precision Medicine: Policy Lessons And Future Directions
Blasimme, A., Fadda, M., Schneider, M., & Vayena, E. (2018) · Health Affairs · doi:10.1377/hlthaff.2017.1558 · Cited by 105 · cited 2×
“The review of data-sharing guidelines by Blasimme et al [17] and a stakeholder consultation of 1329 scientists [18] demonstrated that the importance of data sharing in medical science is not sufficiently recognized.”
BackgroundData use under the NIH GWAS Data Sharing Policy and future directions
Committees, T. N. I. O. H. G. D. S. G. (2014) · Nature Genetics · doi:10.1038/ng.3062 · Cited by 100
Bull, S., Cheah, P. Y., Denny, S., Jao, I., Marsh, V., Merson, L., Shah More, N., Nhan, L. N. T., Osrin, D., Tangseefa, D., et al. (2015) · Journal of Empirical Research on Human Research Ethics · doi:10.1177/1556264615594606 · Cited by 99 · cited 1×
“These data-sharing guidelines aim to safeguard the privacy of study participants when data are used by a researcher to build on existing evidence (secondary research) and thereby maximize benefits for the public [12].”
BackgroundTaichman, D. B., Sahni, P., Pinborg, A., Peiperl, L., Laine, C., James, A., Hong, S.-T., Haileamlak, A., Gollogly, L., Godlee, F., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1028 · Cited by 96
Clinical trials bureaucracy: unintended consequences of well-intentioned policy
Califf, R. M. (2006) · Clinical Trials · doi:10.1177/1740774506073173 · Cited by 91 · cited 1×
“There are ethical complexities as well: large sample sizes are often possible only by recruiting participants from low-income countries owing to their larger populations and (often) poor clinical trial oversight and regulatory mechanisms [19,31].”
BackgroundHarrison, P. W., López, R., Rahman, N., Allen, S. G., Aslam, R., Buso, N., Cummins, C. A., Fathy, Y., Félix, E., Glont, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab417 · Cited by 84 · cited 1×
“The COVID-19 pandemic is considered a booster for clinical data sharing because many researchers and working groups have strongly advocated it [5-8].”
BackgroundOverview and experience of the YODA Project with clinical trial data sharing after 5 years
Ross, J. S., Waldstreicher, J., Bamford, S., Berlin, J. A., Childers, K., Desai, N. R., Gamble, G. M., Gross, C. P., Kuntz, R. E., Lehman, R., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.268 · Cited by 81
Beyond open data: realising the health benefits of sharing data: Table 1
Pisani, E., Aaby, P., Breugelmans, J. G., Carr, D. L., Groves, T., Helinski, M. E. H., Kamuya, D., Kern, S. E., Littler, K., Marsh, V., et al. (2016) · BMJ · doi:10.1136/bmj.i5295 · Cited by 80
Lounsbury, O., Roberts, L. F., Goodman, J., Batey, P., Naar, L., Flott, K., Lawrence‐Jones, A., Ghafur, S., Darzi, A. W., & Neves, A. L. (2021) · Journal of Medical Internet Research · doi:10.2196/22744 · Cited by 56
Coady, S. A., & Wagner, E. (2013) · Trials · doi:10.1186/1745-6215-14-201 · Cited by 55
Standard operating procedures for clinical practice
Sathyanarayana Rao, T., Radhakrishnan, R., & Andrade, C. (2011) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.75542 · Cited by 45 · cited 1×
“We included studies that described any clinical trial data–sharing policies or standard operating procedures, which are defined as detailed, written instructions to achieve uniformity of the performance of a specific function upholding the goal of the Good Clinical Practice guideline [67].”
MethodSmith, C. T., Hopkins, C., Sydes, M., Woolfall, K., Clarke, M., Murray, G., & Williamson, P. (2015) · Trials · doi:10.1186/1745-6215-16-s2-o1 · Cited by 45
Medical journal requirements for clinical trial data sharing: Ripe for improvement
Naudet, F., Siebert, M., Pellen, C., Gaba, J., Axfors, C., Cristea, I., Danchev, V., Mansmann, U., Ohmann, C., Wallach, J. D., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003844 · Cited by 43 · cited 2×
“Clinical trial data sharing is defined as “sharing of anonymized, patient-level clinical trial data through established platforms thereby enhancing transparency, thus maximizing value of research and creating opportunities for external researchers to reanalyze, synthesize, replicate, and build upon previous evidence”…”
BackgroundSharing Public Health Research Data
Parker, M. J., & Bull, S. (2015) · Journal of Empirical Research on Human Research Ethics · doi:10.1177/1556264615593494 · Cited by 41
COVID-19 trials: declarations of data sharing intentions at trial registration and at publication
Li, R., von Isenburg, M., Levenstein, M., Neumann, S., Wood, J., & Sim, I. (2021) · Trials · doi:10.1186/s13063-021-05104-z · Cited by 36
Approaches and Costs for Sharing Clinical Research Data
Wilhelm, E. E., Oster, E., & Shoulson, I. (2014) · JAMA · doi:10.1001/jama.2014.850 · Cited by 36
Pencina, M. J., Louzao, D. M., McCourt, B. J., Adams, M. R., Tayyabkhan, R. H., Ronco, P., & Peterson, E. D. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.11.002 · Cited by 27 · cited 7×
“The trial agencies specified in these documents were a for-profit pharmaceutical firm (GlaxoSmithKline [GSK]-sponsored clinical trials) [72], an academic institution (Yale Open Data Access) [70], a pharmaceutical-academia collaboration (Supporting Open Access for Researchers) [73], and a nonprofit regulatory agency (I…”
BackgroundInfluentialIndia's Product Patent Protection Regime: Less or More of “Pills for the Poor”?
Sampath, P. G. (2006) · The Journal of World Intellectual Property · doi:10.1111/j.1422-2213.2006.00308.x · Cited by 27 · cited 1×
“For-profit pharmaceutical corporations often resist, or lack interest in, data-sharing efforts through their data-exclusivity practices [26,27].”
BackgroundClinical trial data sharing: here’s the challenge
Kochhar, S., Knoppers, B. M., Gamble, C. L., Chant, A., Koplan, J. P., & Humphreys, G. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-032334 · Cited by 27
From Patient to Patient — Sharing the Data from Clinical Trials
Haug, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1605378 · Cited by 23 · cited 2×
“At a macrolevel, this could be due to issues pertaining to IPR, differences across regulatory guidelines in high-income countries and LMICs, the variations in commercial interests of funding sources, and the potentially high economic benefits from data exclusivity [80-82].”
BackgroundChallenges to complete and useful data sharing
Mbuagbaw, L. C. E., Foster, G., Cheng, J., & Thabane, L. (2017) · Trials · doi:10.1186/s13063-017-1816-8 · Cited by 23
Solutions to COVID-19 data sharing
Fegan, G., & Cheah, P. Y. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30273-9 · Cited by 20
Classification of processes involved in sharing individual participant data from clinical trials
Ohmann, C., Canham, S., Banzi, R., Kuchinke, W., & Battaglia, S. (2018) · F1000Research · doi:10.12688/f1000research.13789.2 · Cited by 14
Zink, A., & Silman, A. J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080598 · Cited by 13 · cited 1×
“Data sharing from cross-border or multicountry and multisite randomized controlled clinical trials are generally not governed by a single (or even comparable) national legislation [29,30].”
Background(2020) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-349-95988-4_648 · Cited by 7
European Medicines Agency changes policy on clinical trial data publication
Watson, R. (2014) · BMJ · doi:10.1136/bmj.g4073 · Cited by 7
Frisby, T., & Contreras, J. L. (2020) · Data & Policy · doi:10.1017/dap.2020.9 · Cited by 6
Rockhold, F. W. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx123 · Cited by 5 · cited 2×
“At a macrolevel, this could be due to issues pertaining to IPR, differences across regulatory guidelines in high-income countries and LMICs, the variations in commercial interests of funding sources, and the potentially high economic benefits from data exclusivity [80-82].”
BackgroundTaubman, A. S., Wager, H., & Watal, J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108883511.024 · Cited by 5
Clinical Trial Data: Share and Share Alike?
Mitka, M. (2015) · JAMA · doi:10.1001/jama.2015.481 · Cited by 2
The draft national pharmaceuticals policy: concerns relating to data exclusivity and price control
Srinivasan, S. (2006) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2006.047 · Cited by 2 · cited 1×
“For-profit pharmaceutical corporations often resist, or lack interest in, data-sharing efforts through their data-exclusivity practices [26,27].”
Background
Research works printed but not linked: 3
- 't Hoen, EF, 2009, The global politics of pharmaceutical monopoly power: drug patents, access, innovation. The application of the WTO Doha declaration on TRIPS public health
- 2013, Sharing clinical research data: workshop summary
- Chakrabarti, G, 2014, J Intellect Prop Rights, 19, 325
Cited by
Financial Technology-Enabled Sustainable Finance for Small- and Medium-Sized Enterprises
Tanchangya, T., Islam, N., Naher, K., Mia, M. R., Chowdhury, S., Sarker, S. R., & Rashid, F. (2025) · Environment Innovation and Management · doi:10.1142/s3060901125500061 · Cited by 58
Coccia, M. (2024) · Contributions to management science · doi:10.1007/978-3-031-58359-9_5 · Cited by 24
Open Video Data Sharing in Developmental and Behavioural Science
Marschik, P. B., Kulvičius, T., Flügge, S., Widmann, C. A. A., Nielsen‐Saines, K., Schulte‐Rüther, M., Hüning, B. M., Bölte, S., Poustka, L., Sigafoos, J., et al. (2022) · iScience · doi:10.1016/j.isci.2023.106348 · Cited by 21
Khan, K. S., Fawzy, M., & Chien, P. F. W. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14837 · Cited by 20
“95,96 For this reason, an international multi-stakeholder consensus highlights the responsibility RCT authors have to keep deidentified raw data in case they are required to address any post-publication complaints.”
BackgroundLabkoff, S. E., Quintana, Y., & Rozenblit, L. (2024) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocae024 · Cited by 18
Metadata
- Authors
- Gudi, N., Kamath, P., Chakraborty, T., Jacob, A. G., Parsekar, S. S., Sarbadhikari, S. N., & John, O.
- Affiliations
- George Institute for Global Health (IN)
- Manipal Academy of Higher Education (IN)
- Corresponding author
- John, Oommen
- ORCID
- Venue
- Journal of Medical Internet Research
- Publisher
- JMIR Publications Inc.
- Published
- 2022-05-04
- Volume
- 24
- Issue
- 5
- Pages
- e33591
- ISSN
- 1438-8871 (ISSN-L)
- PMC
- PMC9118011
- OpenAlex
- W4229049670
- Cited by
- 31
- References
- 53
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 6 · 2023: 6 · 2022: 2
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Medical Internet Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- World Health Organization (COVID-19, P20-00060)
- Topics
- Physical Sciences › Computer Science › Information Systems › Research Data Management Practices
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
- Keywords
- clinical trial data sharing, regulatory framework, data sharing policy, data sharing agreements, informed consent, data exclusivity, open access data sharing, low- and middle-income countries, COVID-19 pandemic, public health emergencies, research collaboration, data sharing incentives, harmonization
- MeSH terms
- COVID-19, Humans, Informed Consent, Poverty, Information Dissemination, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
